Esperion Closes Corstasis Acquisition for Enbumyst

Esperion Therapeutics (NASDAQ: ESPR) has closed its acquisition of Corstasis Therapeutics, a commercial-stage biopharmaceutical company focused on outpatient therapies for edema tied to cardiovascular and hepatic and renal disease. The deal brings Enbumyst™ (bumetanide nasal spray) into Esperion’s cardiovascular franchise.

Enbumyst is the first and only FDA-approved nasal spray loop diuretic. The FDA approved Enbumyst in September 2025 for edema associated with congestive heart failure, as well as hepatic and renal disease in adults. Esperion said it will use its cardiovascular commercial infrastructure, including payer engagement, prescriber education, and field execution, to drive adoption and patient access.